Gusto Global, a leading microbiome discovery platform company focused on restoring a healthy microbiome, has developed novel consortia of bacteria that shows promise as a “breakthrough” therapy for treating Crohn’s disease and ulcerative colitis in […]
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented […]
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the completion of its target enrollment […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an […]
About 12,000 bacteria and viruses collected in a sampling from public transit systems and hospitals around the world from 2015 to 2017 had never before been identified, according to a study by the International MetaSUB […]
Basel, Switzerland and Hørsholm, Denmark, 31 May 2021 – Following GMP inspections by Swissmedic at Bacthera’s drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera’s drug substance facility in Hørsholm, […]
While the consequences of the COVID-19 pandemic have been devastating, it has also served as a key milestone on the road to understand the human microbiome and how it affects our health. Since the […]
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]
Martin J. Blaser, MD, has been awarded the 2020 Prize Medal by the Microbiology Society of Great Britain in recognition of his study of the microbiome and its interactions within the human body that provide […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. […]
Living in and on our bodies are trillions of microbial cells belonging to thousands of bacterial species – our microbiome. These microbes play key roles in human health, but little is known about their evolution. […]